In contrast, another study examining 71 patients with HER2-positive breast cancer treated with Trastuzumab found that individuals with AG or GG genotypes had poorer DFS than those with the AA genotype (P = 0.01) [37]. The gene discussed is ERBB2; the disease is breast carcinoma.